Community Practice Connections™: Utilizing Real-World Evidence to Optimize Outcomes in Type 2 Diabetes – Reducing Cardiovascular Disease & CV Risk

Released On
September 10, 2021

Expires On
September 10, 2022

Media Type

Completion Time
90 minutes

Cardiology, Endocrinology

Cardiovascular Disease, Diabetes

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.


This activity is supported by an educational grants from Boehringer Ingelheim and Eli Lilly.

Credit Available

  • Physicians — maximum of 1.5 AMA PRA Category 1 Credit(s)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This educational program is directed toward all attendees of the 2021 ASCP Internal Medicine Meeting. We invite primary care physicians, diabetologists, endocrinologists, cardiologists, certified diabetes educators, nurse practitioners, physician assistants, and other health care providers who treat patients with T2D to participate in the online enduring program.

Program Overview

Type 2 diabetes (T2D) and cardiovascular disease (CVD) share several risk factors as well as targeted treatment strategies. Although impaired glucose metabolism plays a central role in the pathology of CV complications in patients with T2D, several studies have demonstrated that CV risk cannot necessarily be reduced simply by achieving a therapeutic glucose goal. The focus on glucose control is shifting; it is expanding to include a comprehensive and ongoing assessment of patients’ CV risk.

This Community Practice Connection™ program provides an in-depth review of some of the key highlights from the webcast Utilizing Real-World Evidence to Optimize Outcomes in Type 2 Diabetes Regarding Cardiovascular Disease and CV Risk, held at the ASPC 2021 Internal Medicine meeting in July 2021. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with T2D and CVD, putting recent trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Review current treatment guidelines for the reduction of CVD risk in patients with T2D
  • Evaluate the real-world evidence for reducing CV events and hospitalization to improve outcomes for patients with T2D
  • Apply emerging clinical data on issues concerning the treatment and prevention of CVD in patients with T2D




President, American Society for Preventive Cardiology
Director, Preventative Cardiology
CGH Medical Center
Sterling, IL


Harold Edward Bays, MD, FOMA, FTOS, FACC, FNLA, FASPC

Medical Director and President
Louisville Metabolic and Atherosclerosis Research Center
Louisville, KY


Pam R. Taub, MD, FACC, FASPC

Director, Step Family Foundation Cardiovascular Rehabilitation and Wellness Center
Professor of Medicine
Division of Cardiovascular Medicine
UC San Diego School of Medicine
La Jolla, CA

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.


  • Consultant: Amarin, AstraZeneca, Kowa, Merck, Resverlogix, Theravance
  • Shareholder: Amarin, Amgen, Esperion, Novo-Nordisk

Harold Edward Bays, MD, FOMA, FTOS, FACC, FNLA, FASPC

  • Grant research support: 89bio, Acasti Pharma, Akcea Therapeutics, Allergan, Alon MedTech/Epitomee, Amarin, Amgen, AstraZeneca, Axsome Therapeutics, Biohaven Pharmaceuticals, Bionime, Boehringer Ingelheim, CiVi Biopharma, Eli Lilly and Company, Esperion Therapeutics, Evidera, Gan & Lee Pharmaceuticals, Home Access Health Corporation, Janssen, Johnson & Johnson, Lexicon Pharmaceuticals, Matinas BioPharma, Merck & Co, Metavant Sciences, Novartis Pharmaceuticals Corporation, Novo Nordisk, Pfizer, Regeneron Pharmaceuticals, Sanofi, Selecta Biosciences, Timi Pharmaceuticals, Urovant Sciences
  • Consultant: 89bio, Amarin, Esperion Therapeutics, Gelesis, Matinas BioPharma
  • Shareholder: Esperion Therapeutics, Novo Nordisk

Pam R. Taub, MD, FACC, FASPC, has no relevant financial relationships with ineligible companies.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Instructions for Participation and Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.
You may immediately download your certificate.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.